
PATENT

May 28, 2002





IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Rostyslav Stoika et al.

Serial No.

09/687,911

Filed: For:

October 13, 2000

MODULATING ACTIVATION OF LYMPHOCYTES AND SCREENING POTENTIAL IMMUNOMODULATING

AGENTS BY TARGETING PITUITARY TUMOR

TRANSFORMING GENE (PTTG) EXPRES PROCEIVED

AND/OR FUNCTION

Examiner:

Unknown

JUN 1 4 7902

Unit:

TECH CENTER 1600,2000

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents Washington, D. C. 20231

Dear Sir:

I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS FIRST CLASS MAIL IN AN ENVELOPE ADDRESSED TO THE ASSISTANT COMMISSIONER FOR PATENTS May 28, 2002 WASHINGTON, D. C. 20231, ON May 28, 2002 (DATE OF SIGNATURE)

Applicant's attorney submits herewith Form PTO-1449,

"Information Disclosure Statement" by Applicant referencing patents and/or other literature of which he is aware, that he believes may be material to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 C.F.R. § 1.56.

A copy of each of the disclosed patent documents and other references listed as other documents Nos. 53-54are not being submitted herewith, because under Rule 37 C.F.R. § 1.98(d) this art was previously cited by the Examiner and/or the Applicant in connection with related application U.S. Serial No. 09/569,956, filed May 12, 2000. This previously filed Application was cited by applicant in this present Application per 35 U.S.C. § 120.

The filing of this Supplemental Information Disclosure statement shall not be construed as a representation that a search has been made (37 C.F.R. 1.97(g)), an admission that the information cited is, or is considered to be, material to patentability or that no other material information exists (37 C.F.R. 1.97(h)). Further the filing of this Supplemental Information Disclosure statement shall not be construed as an admission against interest in any manner.

It is believed that this Supplemental Information Disclosure statement is being filed before the mailing of a first office action on the merits. However, the Commissioner is hereby authorized to credit overpayments or charge any fees required under 37 C.F.R. 1.16 or C.F.R. 1.17 to Deposit Account No. 50-1597.

Respectfully submitted,

Nisan A. Steinberg, Ph.D. Registration No. 40,345

SIDLEY AUSTIN BROWN & WOOD LLP 555 West Fifth Street Los Angeles, California 90013-1010

Ofc: 213/ 896-6665 Fax: 213/896-6600

COPY OF PAPERS ORIGINALLY FILED

•		ORIG	SINALLY FILED				
Date Mailed: May 28, 2002		•				Page 1 of 1	
		DOCKET N	IO.	SERIAL NO.			
	CEDAR-44649 (188			09/687,911			
List of Patents and Publications for			tyslav Stoika et al.				
Applicants Supplemental Information	FILING DATE:			GROUP ART UNIT			
Disclosure Statement	October 13, 2000						
JUN 0 6 2002 S		U.S. PATEN	T DOCUMENTS		SUB	FILING DATE	
EXAMINATION INITIAL RADI MARTINE CUMENT NUMBER	ER	DATE	NAME	CLASS	CLASS	FILING DATE	
					ļ		
					~FIV	En	
				- HE	UEIV		
					IN 1 4 20	02	
				-]) 4]. 		
				TEOU	ENTER 16	hn/2900	
				IEUN	LIVILITIO	00,2000	
i I	- 1			1	1	i	

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRANSLATION YES	Translation No
	WO 93/25712	23.12.93	PCT				
-							

OTHER ART (Including Author, title, Date, Pertinent Pages, Etc.)

53.	Dominguez, Africa et al., hpttg, a human homologue of rat pttg, is overexpressed in hematopoietic neoplasmas. Evidence for a transcriptional activation function of Hpttg, Oncogene, Vol. 17, pp. 2187-2195 (1998).
54.	XP-002193233, Chen, Leilei et al., Identification of the human pituitary tumor transforming gene (hPTTG) family: molecular structure, expression, and chromosomal localization, Gene, Vol. 248, pp. 41-50 (2000).

EXAMINER	DATE CONSIDERED;			
<u></u>				
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if				
not in conformance and not considered. Include copy of this form with next communication to applicant.				